The United States Food and Drug Administration (FDA) granted final approval as the first treatment for COVID-19 to the antiviral of Gilead Remdesivir, to date the only one with authorization from the regulator to treat the disease.
In May the antiviral de Gilead Sciences received the emergency authorization, a formula to allow the use during the pandemic of the treatment still in its experimental stage, and now the FDA granted the final approval for cases of hospitalized COVID-19 patients.
Doubts about its effectiveness
Remdesivir has allowed shorter recovery periods in some severe cases of COVID-19, although the World Health Organization (WHO) recently considered, after analyzing provisional data, that the antiviral as well as others that have been administered to COVID-19 patients, has an almost negligible impact on reducing mortality.
The main American epidemiologist, Dr. Anthony Fauci, has defended the use of Remdesivir, which is being administered to patients in the United States and with which the President of the United States was treated, Donald Trump, during his convalescence at the beginning of the month.
With the authorization received today, Remdesivir it becomes the only treatment authorized in the US for covid-19, which has infected more than 41 million people worldwide, although there are other treatments that already have emergency authorization such as the use of plasma.
“It is incredible that in less than a year since the first reports of infected by the disease known as COVID-19 in the United States, we have a treatment it is available to all patients who need it, “Gilead CEO Daniel O’Day said in a statement.
The pharmaceutical company expects to manufacture more than two million doses of treatment, which is administered intravenously, and multiply that production capacity during 2021.